CalciMedica discontinues Phase 2 KOURAGE trial, extends cash runway to Q4 2026

CalciMedica, Inc.

Phase 2 KOURAGE trial discontinued following IDMC recommendation.
Cash runway guidance updated: existing cash, equivalents, and short-term investments expected to fund operations into Q4 2026.
Previously disclosed guidance expected funding into second half of 2026.
No specific financial amounts or trial data disclosed in filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.